ENANTA PHARMACEUTICALS INC Quarterly Costs and Expenses in USD from Q1 2015 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Total costs of sales and operating expenses for the period.
Summary
Enanta Pharmaceuticals Inc quarterly/annual Costs and Expenses history and growth rate from Q1 2015 to Q3 2024.
  • Enanta Pharmaceuticals Inc Costs and Expenses for the quarter ending September 30, 2024 was $44.5M, a 11% decline year-over-year.
  • Enanta Pharmaceuticals Inc Costs and Expenses for the twelve months ending September 30, 2024 was $189M, a 12.5% decline year-over-year.
  • Enanta Pharmaceuticals Inc annual Costs and Expenses for 2024 was $189M, a 12.5% decline from 2023.
  • Enanta Pharmaceuticals Inc annual Costs and Expenses for 2023 was $216M, a 3.05% increase from 2022.
  • Enanta Pharmaceuticals Inc annual Costs and Expenses for 2022 was $210M, a 1.63% increase from 2021.
Costs and Expenses, Trailing 12 Months (USD)
Costs and Expenses, Quarterly (USD)
Costs and Expenses, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $189M $44.5M -$5.5M -11% Jul 1, 2024 Sep 30, 2024 10-K 2024-11-27
Q2 2024 $195M $42.2M -$13.4M -24.2% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-07
Q1 2024 $208M $49.8M -$7.43M -13% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-08
Q4 2023 $216M $52.9M -$709K -1.32% Oct 1, 2023 Dec 31, 2023 10-Q 2024-02-08
Q3 2023 $216M $50M +$2.6M +5.48% Jul 1, 2023 Sep 30, 2023 10-K 2024-11-27
Q2 2023 $214M $55.6M +$3.59M +6.89% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-07
Q1 2023 $210M $57.2M +$4.68M +8.91% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-08
Q4 2022 $206M $53.6M -$4.46M -7.68% Oct 1, 2022 Dec 31, 2022 10-Q 2024-02-08
Q3 2022 $210M $47.4M -$9.94M -17.3% Jul 1, 2022 Sep 30, 2022 10-K 2024-11-27
Q2 2022 $220M $52M -$3.45M -6.22% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-08
Q1 2022 $223M $52.6M +$2.73M +5.48% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-09
Q4 2021 $221M $58.1M +$14M +31.8% Oct 1, 2021 Dec 31, 2021 10-Q 2023-02-08
Q3 2021 $207M $57.3M +$13.9M +32% Jul 1, 2021 Sep 30, 2021 10-K 2023-11-22
Q2 2021 $193M $55.5M +$14M +33.6% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-08
Q1 2021 $179M $49.8M +$10.3M +26.2% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-09
Q4 2020 $168M $44M +$4.34M +10.9% Oct 1, 2020 Dec 31, 2020 10-Q 2022-02-10
Q3 2020 $164M $43.4M -$1.47M -3.27% Jul 1, 2020 Sep 30, 2020 10-K 2020-11-25
Q2 2020 $166M $41.5M +$893K +2.2% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-09
Q1 2020 $165M $39.5M -$1.44M -3.52% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-10
Q4 2019 $166M $39.7M -$2.33M -5.55% Oct 1, 2019 Dec 31, 2019 10-Q 2021-02-09
Q3 2019 $168M $44.9M +$12.1M +37% Jul 1, 2019 Sep 30, 2019 10-K 2020-11-25
Q2 2019 $156M $40.6M +$5.99M +17.3% Apr 1, 2019 Jun 30, 2019 10-K 2020-11-25
Q1 2019 $150M $40.9M +$13.7M +50.6% Jan 1, 2019 Mar 31, 2019 10-K 2020-11-25
Q4 2018 $137M $42M +$18.3M +77.1% Oct 1, 2018 Dec 31, 2018 10-K 2020-11-25
Q3 2018 $118M $32.8M +$11.1M +51.4% Jul 1, 2018 Sep 30, 2018 10-K 2019-11-27
Q2 2018 $107M $34.6M +$14M +67.7% Apr 1, 2018 Jun 30, 2018 10-K 2019-11-27
Q1 2018 $93.2M $27.2M +$8.73M +47.3% Jan 1, 2018 Mar 31, 2018 10-K 2019-11-27
Q4 2017 $84.5M $23.7M +$6.27M +35.9% Oct 1, 2017 Dec 31, 2017 10-K 2019-11-27
Q3 2017 $78.2M $21.6M +$5.69M +35.7% Jul 1, 2017 Sep 30, 2017 10-K 2018-11-29
Q2 2017 $72.5M $20.6M +$5.57M +37% Apr 1, 2017 Jun 30, 2017 10-K 2018-11-29
Q1 2017 $66.9M $18.5M +$4.9M +36.1% Jan 1, 2017 Mar 31, 2017 10-K 2018-11-29
Q4 2016 $62M $17.5M +$4.61M +35.9% Oct 1, 2016 Dec 31, 2016 10-K 2018-11-29
Q3 2016 $57.4M $15.9M Jul 1, 2016 Sep 30, 2016 10-K 2018-11-29
Q2 2016 $15.1M +$5.17M +52.3% Apr 1, 2016 Jun 30, 2016 10-Q 2017-08-09
Q1 2016 $13.6M +$4.76M +54.1% Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-10
Q4 2015 $12.9M Oct 1, 2015 Dec 31, 2015 10-Q 2017-02-09
Q2 2015 $9.9M Apr 1, 2015 Jun 30, 2015 10-Q 2016-08-09
Q1 2015 $8.81M Jan 1, 2015 Mar 31, 2015 10-Q 2016-05-10
* An asterisk sign (*) next to the value indicates that the value is likely invalid.